Project Immortality
Project Immortality applies iPSC-derived cellular systems and CRISPR-Cas9 genomic editing to the problem of aging-related organ failure. Every available treatment for aging-related organ failure — whether a drug, a supplement, or a surgical intervention — addresses a downstream consequence rather than the cause. The evidence points to a single upstream convergence point: the lifelong accumulation of unrepaired DNA damage. When cells lose the ability to maintain their genome, every other hallmark of aging follows. Project Immortality takes a different approach. Rather than managing the consequences of cellular aging, we engineer cells that are intrinsically resistant to its causes — modifying iPSC-derived stem cells at the genomic level before transplantation, with differentiation programmed to activate only upon reaching the target tissue. The goal is not to slow the clock. It is to replace the mechanism that winds it down. Initial indications: ESRD, HFrEF, and IPF.
Key Capabilities
- iPSC line generation with GFP/PiggyBac ITR CRISPR-Cas9 constructs
- Single-cell sorting and clonal expansion via multiple instruments (Cytena C.SIGHT 2.0, MACSQuant Tyto)
- Primary indications: ESRD, HFrEF, IPF — high unmet need, aging-driven prevalence